Effectiveness and safety of empagliflozin: final results from the EMPRISE study
Diabetologia · 2024
DOI: 10.1007/s00125-024-06126-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, 2024. Verfasst von Phyo T Htoo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, …. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
AIMS/HYPOTHESIS: Limited evidence exists on the comparative safety and effectiveness of empagliflozin against alternative glucose-lowering medications in individuals with type 2 diabetes with the broad spectrum of cardiovascular risk. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) cohort study was designed to monitor the safety and effectiveness of empagliflozin periodically for a period of 5 years with data collection from electronic healthcare databases. METHODS: We identified individuals ≥18 years old with type 2 diabetes who initiated empagliflozin or dipeptidyl peptidase-4 inhibitors (DPP-4i) from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we identified four a priori-defined effectiveness outcomes: (1) myocardial infarction (MI) or stroke; (2) hospitalisation for heart failure (HHF); (3) major adverse cardiovascular events (MACE); and (4) cardiovascular mortality or HHF. Safety outcomes included lower-limb amputations, non-vertebral fractures, diabetic ketoacidosis (DKA), acute kidney injury (AKI), severe hypoglycaemia, retinopathy progression, and short-term kidney and bladder cancers. We estimated HRs and rate differences (RDs) per 1000 person-years, overall and stratified by age, sex, baseline atherosclerotic cardiovascular disease (ASCVD) and heart failure. RESULTS: We identified 115,116 matched pairs. Compared with DPP-4i, empagliflozin was associated with lower risks of MI/stroke (HR 0.88 [95% CI 0.81, 0.96]; RD -2.08 [95% CI (-3.26, -0.90]), HHF (HR 0.50 [0.44, 0.56]; RD -5.35 [-6.22, -4.49]), MACE (HR 0.73 [0.62, 0.86]; RD -6.37 [-8.98, -3.77]) and cardiovascular mortality/HHF (HR 0.57 [0.47, 0.69]; RD -10.36 [-12.63, -8.12]). Absolute benefits were larger in older individuals and in those with ASCVD/heart failure. Empagliflozin was associated with an increased risk of DKA (HR 1.78 [1.44, 2.19]; RD 1.59 [1.08, 2.09]); decreased risks of AKI (HR 0.62 [0.54, 0.72]; RD -2.39 [-3.08, -1.71]), hypoglycaemia (HR 0.75 [0.67, 0.84]; RD -2.46 [-3.32, -1.60]) and retinopathy progression (HR 0.78 [0.63, 0.96)]; RD -9.49 [-16.97, -2.10]); and similar risks of other safety events. CONCLUSIONS/INTERPRETATION: Empagliflozin relative to DPP-4i was associated with risk reductions of MI or stroke, HHF, MACE and the composite of cardiovascular mortality or HHF. Absolute risk reductions were larger in older individuals and in those who had history of ASCVD or heart failure. Regarding the safety outcomes, empagliflozin was associated with an increased risk of DKA and lower risks of AKI, hypoglycaemia and progression to proliferative retinopathy, with no difference in the short-term risks of lower-extremity amputation, non-vertebral fractures, kidney and renal pelvis cancer, and bladder cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
- Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, MA, USA.
- Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Global Epidemiology, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
- Global Medical Affairs, Lilly Deutschland GmbH, Bad Homburg vor der Höhe, Germany.
- Division of Renal (Kidney) Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Förderung
- Boehringer Ingelheim
Zitieren
APA
Htoo, P. T., Tesfaye, H., Schneeweiss, S., Wexler, D. J., Everett, B. M., Glynn, R. J., Schmedt, N., Koeneman, L., Déruaz-Luyet, A., Paik, J. M., & Patorno, E. (2024). Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia. https://doi.org/10.1007/s00125-024-06126-3
Vancouver
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, et al. Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia. 2024. doi:10.1007/s00125-024-06126-3
BibTeX
@article{Htoo2024,
author = {Htoo, Phyo T and Tesfaye, Helen and Schneeweiss, Sebastian and Wexler, Deborah J and Everett, Brendan M and Glynn, Robert J and Schmedt, Niklas and Koeneman, Lisette and Déruaz-Luyet, Anouk and Paik, Julie M and Patorno, Elisabetta},
title = {Effectiveness and safety of empagliflozin: final results from the EMPRISE study},
journal = {Diabetologia},
year = {2024},
doi = {10.1007/s00125-024-06126-3}
}
EUVIMED